AI-generated summaries. Verify every claim with the cited sources before acting on them. Read our methodology

← Back to all reports

CADASIL

Recent research efforts aimed at curing CADASIL.

Last updated
Also available in
Français — CADASIL

CADASIL

Overview

CADASIL (cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy) is an inherited disorder of the brain’s small blood vessels caused by a disease-causing variant in NOTCH3. It is usually inherited in an autosomal-dominant pattern, meaning each child of an affected parent has a 50% chance of inheriting the variant. The disorder can cause migraine with aura, mood or psychiatric symptoms, repeated transient ischemic attacks or strokes, slowed thinking, and eventually vascular cognitive impairment or dementia. Symptoms and severity vary substantially by the specific NOTCH3 variant, including its position in the gene. CADASIL GeneReviews (ncbi.nlm.nih.gov)

CADASIL is progressive, but its course is not uniform. In a large natural-history cohort summarized in CADASIL GeneReviews, loss of independent walking occurred at a median age of about 60 years and median age at death was 68 years; these historical figures should not be treated as an individual prediction. There is no approved treatment that prevents, stops, or reverses CADASIL. Current care focuses on controlling vascular risks such as high blood pressure and smoking, treating migraine and mood symptoms, rehabilitation after stroke, and individualized decisions about antiplatelet or anticoagulant medicines. CADASIL GeneReviews (ncbi.nlm.nih.gov)

Scope of Recent Research (2020–present)

Recent CADASIL research has been active but remains a small, largely preclinical field. The dominant questions are whether mutant NOTCH3 causes disease mainly through toxic extracellular protein accumulation, reduced NOTCH3 signaling in vascular “mural” cells such as vascular smooth-muscle cells and pericytes, or both; researchers are also developing human cell models and biomarkers capable of supporting future trials. The field has produced credible therapeutic leads—especially immunotherapy, RNA exon skipping, and gene editing—but remains well before a curative human therapy. NOTCH3 signaling and aggregation review (pmc.ncbi.nlm.nih.gov)

Major Breakthroughs and Emerging Therapies

NOTCH3-directed immunotherapy is the most advanced disease-targeted preclinical strategy. A 2023 study vaccinated CADASIL-model mice with aggregated NOTCH3 extracellular-domain fragments designed to provoke antibodies against pathological NOTCH3 deposits. Four months of treatment reduced NOTCH3 deposition around brain capillaries and lowered circulating NOTCH3 extracellular-domain levels, without evident inflammatory, neuronal, kidney, or vascular-integrity toxicity in that experiment. This is an important proof of principle for clearing a suspected driver of disease, but it did not establish prevention of stroke, cognitive decline, or reversal of established human disease. Active NOTCH3 immunotherapy in mice (pmc.ncbi.nlm.nih.gov)

A related approach aims to restore impaired NOTCH3 signaling rather than remove deposits. The NIH-supported Schepens Eye Research Institute program is humanizing an agonist antibody—an antibody intended to activate NOTCH3—that previously prevented mural-cell loss in mouse models. Its stated preclinical milestones include blood–central nervous system penetration, restoration of a blood NOTCH3 biomarker, rescue of mural-cell loss, and toxicity/pharmacokinetic testing. This approach may be particularly relevant to NOTCH3 variants that reduce receptor signaling, but whether it can help the broader range of CADASIL-causing variants remains unknown. NIH NOTCH3 agonist-antibody award (taggs.hhs.gov)

Gene correction and RNA therapeutics offer the most direct theoretical routes to a cure. In a 2024 study, researchers corrected the NOTCH3 p.R421C mutation in patient-derived induced pluripotent stem cells (iPSCs), vascular smooth-muscle cells, and blood-vessel organoids using adenine base editing. A split adeno-associated virus (AAV) system edited vascular organoids in vitro, demonstrating technical feasibility but not in-body delivery, durable correction, or safety in people. Adenine base editing of CADASIL cells and organoids (sciencedirect.com) A complementary RNA strategy, antisense-oligonucleotide exon skipping, is supported by a 2020 human genetic observation: naturally skipping a mutation-containing NOTCH3 exon was associated with markedly less NOTCH3 aggregation and a milder phenotype in one family. That finding supports the biological rationale for deliberately skipping selected exons, but no therapeutic antisense product has yet entered a CADASIL efficacy trial. Natural NOTCH3 exon skipping (pmc.ncbi.nlm.nih.gov)

Small-molecule and cell-model-guided discovery is also expanding. In 2024, CRISPR base-edited human blood-vessel organoids carrying CADASIL mutations reproduced mural-cell degeneration, extracellular NOTCH3 accumulation, cell death, and abnormal vessel structure; a Rho-associated protein kinase (ROCK) inhibitor partly restored endothelial–mural-cell connections. This is not evidence of a ready-to-use drug, but it identifies a potentially druggable pathway and provides a more human-relevant screening platform than traditional cell cultures alone. CADASIL blood-vessel organoids (pmc.ncbi.nlm.nih.gov)

Clinical Trials and Experimental Approaches

No gene-editing, exon-skipping, antibody, vaccine, or cell-replacement therapy has yet reported clinical efficacy in people with CADASIL. The principal recent interventional study relevant to CADASIL was TREAT-SVDs (NCT03082014), a multicenter randomized crossover trial comparing four-week courses of amlodipine, losartan, and atenolol in people with cerebral small-vessel disease, including 26 participants with CADASIL. Among the 17 CADASIL participants included in the primary efficacy analysis, cerebrovascular reactivity—a magnetic-resonance-imaging measure of blood-vessel responsiveness—improved with amlodipine and losartan relative to atenolol; the trial was not designed to show prevention of stroke, disability, or dementia. TREAT-SVDs trial report TREAT-SVDs registry record (pubmed.ncbi.nlm.nih.gov)

Current registered CADASIL studies are chiefly observational and intended to make later therapeutic trials feasible. The NHLBI-sponsored Natural History Study of CADASIL (NCT05072483) was recruiting as of its July 2, 2026 update and follows affected adults and healthy volunteers with clinical assessments, cognitive testing, biosamples, imaging, and optional skin biopsy over nine years. NHLBI natural-history study (clinicaltrials.gov) The Korean K-CADASIL registry (NCT07497867), sponsored by Jeju National University Hospital, began in July 2023 and plans to follow approximately 500 participants for ten years while building genomic and proteomic resources. K-CADASIL registry (clinicaltrials.gov)

Methodologies and Scientific Approaches

Researchers combine transgenic mouse models, patient-derived iPSCs, vascular smooth-muscle cells, three-dimensional blood-vessel organoids, skin and blood samples, and MRI-based measures of cerebral small-vessel function. These models allow investigators to test whether a therapy reduces extracellular NOTCH3 aggregation, preserves mural cells, restores vessel tone, or corrects mutation-associated molecular changes before exposing people to experimental interventions. CADASIL blood-vessel organoids Active NOTCH3 immunotherapy in mice (pmc.ncbi.nlm.nih.gov)

Biomarker development is a central translational priority. Candidate measures include MRI lesion burden and cerebrovascular reactivity, cognitive outcomes, retinal imaging, and blood levels of the NOTCH3 extracellular domain. The agonist-antibody program explicitly uses circulating NOTCH3 extracellular domain as a target-engagement biomarker, while the U.S. Food and Drug Administration awarded the University of Wisconsin–Madison a four-year, $5 million grant to evaluate retinal-imaging biomarkers in people with CADASIL. NIH NOTCH3 agonist-antibody award FDA rare-neurodegenerative-disease grants (taggs.hhs.gov)

Leading Institutions and Funding

Major disease-targeted work includes the Schepens Eye Research Institute/Mass Eye and Ear and Harvard-affiliated investigators developing a humanized NOTCH3 agonist antibody; Sun Yat-sen University investigators developing base-editing approaches in patient-derived vascular cells and organoids; and the NHLBI Clinical Center’s long-term natural-history study. The NIH/NINDS cooperative agreement for antibody humanization, U01NS119560, recorded a total of $1,529,075 in awards through fiscal year 2025, with a zero-dollar administrative continuation recorded in May 2026. NIH NOTCH3 agonist-antibody award Adenine base editing of CADASIL cells and organoids NHLBI natural-history study (taggs.hhs.gov)

Patient-led organizations are helping build the trial infrastructure that a rare disease needs. cureCADASIL reports that its Chan Zuckerberg Initiative patient-partnered program initially provided $800,000 in 2022 and an additional $800,000 through 2026 for Mount Sinai-led cellular disease models, drug screening, and studies of immune mechanisms; the organization also announced an $80,000 investigator-initiated CADASIL research grant for the February 2026–January 2027 period. cureCADASIL CZI program cureCADASIL research grant (curecadasil.org)

Strengths, Limitations, and Challenges

The field’s strength is that it now has several mechanistically distinct strategies: remove toxic NOTCH3 aggregates, restore deficient receptor signaling, skip mutation-containing RNA segments, directly correct a mutation, or identify downstream drug targets. The recent use of genetically precise, patient-relevant vascular organoids is especially valuable because CADASIL is fundamentally a disease of interactions among vessel-wall cells, not simply an isolated neuron disorder. CADASIL blood-vessel organoids NOTCH3 signaling and aggregation review (pmc.ncbi.nlm.nih.gov)

The limitations are substantial. CADASIL involves hundreds of NOTCH3 variants, some of which may act through different balances of protein aggregation and signaling loss, making a universal therapy difficult. A treatment must also safely reach widespread brain arterioles and mural cells, avoid disrupting normal NOTCH3 functions, demonstrate durable benefit despite slow clinical progression, and be tested in small, geographically dispersed patient populations. Gene editing adds mutation-specific design, delivery, immune-response, and off-target-editing challenges; immunotherapy must show that lowering deposits leads to meaningful clinical benefit rather than a biomarker-only effect. Adenine base editing of CADASIL cells and organoids Active NOTCH3 immunotherapy in mice (sciencedirect.com)

Outlook and Future Directions

As of September 10, 2026, a cure for CADASIL is not close in clinical-development terms, because the leading disease-targeted programs remain in cells or animals and human studies are still centered on natural history and biomarkers. The milestones most worth watching are demonstration that a NOTCH3 antibody or vaccine improves vessel function and clinical-like outcomes in rigorous animal models; safe, efficient delivery of RNA or gene-editing therapies to cerebral mural cells; replication of candidate drug effects in multiple patient-derived organoid lines; and selection of validated biomarkers and patient cohorts for a first disease-modifying trial. NIH NOTCH3 agonist-antibody award NHLBI natural-history study (taggs.hhs.gov)

References

Don't see your disease? Request a report